摘要
目的:研究米氮平对慢性阻塞性肺疾病(COPD)合并抑郁焦虑患者生活质量的影响。方法:采用汉密尔顿焦虑量表(HAMA)及汉密顿抑郁量表(HAMD)(17项)测量心理状况,将存在轻中度焦虑、抑郁症状的48例COPD患者随机分为米氮平组(26例)及对照组(22例),疗程4周。对照组只给常规治疗,米氮平组予米氮平10mg～30mg/d。治疗前后检测患者COPD的各项肺功能指标并用圣乔治呼吸问卷(SGRQ)评价生活质量,应用TESS评定治疗中出现的不良反应。结果:米氮平治疗4周末,有效率100%,HAMA及HAMD评分明显降低(P<0.05),FEV1占预计值%及FEV1/FVC(%)均有明显改善(P<0.05),生活质量各评分与对照组比较,差异有显著性意义(P<0.05)。结论:米氮平能改善COPD患者的焦虑及抑郁症状,提高生活质量。
group only conventional drugs were used , while in the treatment group mirtazapine 10 mg -30 mg per day, p.o.was given besides the routine treatment .Results：The effective ratio in the observation group was 100%.In the observation group , the scores of HAMA and HAMD were decreased significantly（P＆lt;0.05）.there was a significant difference in the scores of SGRQ and the lung functions after treat -ment （ P＆lt;0.05） .No severe side-effects occurred .Conclusion：Mirtazapine should be effective and safe in the treatment of depression and anxiety in the patients with COPD ,and improve their quality of life .
出处
《中国伤残医学》
2014年第6期31-33,共3页
Chinese Journal of Trauma and Disability Medicine
基金
新乡医学院重点学科开放课题(ZD200993)
关键词
慢性阻塞性肺疾病
生存质量
焦虑
抑郁
Pulmonary disease,Chronic obstructive
Quality of life
Depression
Mirtazapine
